News – Page 1052 – Endpoints News

Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?

8 years ago

Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide

8 years ago

AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight ...

8 years ago

Roche and Takeda try on Emulate’s 'organ chip' tech for R&D

8 years ago

Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact

8 years ago

FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market

8 years ago

Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis

8 years ago

Roivant Sciences in exclusive joint venture talks with Arbutus; DBV gets green light to submit peanut allergy patch

8 years ago

White House: Merck and others hit by NotPetya were collateral damage in Russia’s cyberwar on the Ukraine

8 years ago

Well, that got awkward. Arcturus fires back at ex-CEO Joe Payne

8 years ago

Ex-Axovant COO Marion McCourt lands at Regeneron; GT Biopharma elevates Shawn Cross to CEO in exec reshuffle

8 years ago

The FDA raises hopes for Alzheimer's drugs with a new set of draft rules. But are they going too far?

8 years ago

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

8 years ago

FDA advisory group rejects Pacira’s pitch for expanded use of pain drug

8 years ago

Roche pays $1.9B for Ex-Googlers’ tech startup Flatiron Health

8 years ago

Aradigm loses CEO, CMO and CFO following regulatory disaster; Omeros shares go up on positive results for blood clot ...

8 years ago

Silicon Valley celebs chip into $250M round for age-fighting startup Celularity. Placenta-based CAR-Ts on the ...

8 years ago

Bioverativ inks $100M gene therapy deal with Oxford BioMedica

8 years ago

Pfizer, Merck KGaA say their PD-L1 Bavencio also flunked PhIII in the all-important lung cancer field

8 years ago

After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access

8 years ago

Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus

8 years ago

CureVac to develop mRNA-based flu, malaria vaccines with new Gates Foundation grants

8 years ago

FDA's Gottlieb outlines new goals in budget plan, looking to spur drug reviews

8 years ago

Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'

8 years ago

First page Previous page 1049 1050 105110521053 1054 1055 Next page Last page